bluebird bio (BLUE) Misses Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bluebird Bio (BLUE) PT Lifted to $119 at Piper Jaffray
February 26, 2015 8:43 AM ESTPiper Jaffray analyst Joshua Schimmer raised his price target on Overweight-rated Bluebird Bio (NASDAQ: BLUE) to $119.00 (from $112.00) following Q4 earnings.
Schimmer commented, "BLUE released 4Q14 earnings Wednesday evening disclosing a cash/cash equivalent balance of $492.0M. The company continues to advance its... More
